Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 331 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pelvic Neoplasm Clear all

Conditions: Cervical Cancer, Endometrial Cancer
Interventions: cisplatin, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 151
States / cities: Auburn, California • Cameron Park, California • Carmichael, California + 103 more

Conditions: Prostate Cancer
Interventions: ePURT 5Gy x 5 fractions with single HDR boost of 15Gy; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cervical Carcinoma, Endometrial Carcinoma, Endometriosis, Pelvic Inflammatory Disease
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Other · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
Interventions: enfortumab vedotin (EV), pembrolizumab, cisplatin, carboplatin, gemcitabine; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 83
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
Interventions: bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Radiation Therapy Complication, Tumor Neck, Tumor Abdomen
Interventions: Spatially Fractionated Radiation (GRID) Therapy; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Uterine Fibroids, Leiomyoma, Menstrual Pain
Interventions: Elix Daily Harmony; Dietary Supplement
Lead sponsor: Zenchi, Inc.; Industry
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: oxaliplatin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 11
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more

Conditions: Gynecologic Cancer
Interventions: Single digit pelvic exam; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin; Biological · Procedure · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more

Conditions: Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Interventions: sterile water irrigation, Gemcitabine; Procedure · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Hypofractionated Radiation Therapy; Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Prostate Cancer
Interventions: Drug: 99mTc-MIP-1404; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Duarte, California • Rochester, Minnesota • New York, New York + 7 more

Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions: Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 429
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more

Conditions: Prostate Cancer
Interventions: Physical Therapy; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Lymphoceles, Prostate Cancer
Interventions: Intuitive Vessel Sealer; Device
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Cell Carcinoma of the Bladder
Interventions: vorinostat, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Malignant Primary Pelvic Neoplasm
Interventions: Electronic Health Record Review, Physical Performance Testing, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • White River Junction, Vermont

Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions: trastuzumab, paclitaxel, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Abnormal Uterine Bleeding, Uterine Bleeding, Fibroid Uterus, Surgery
Interventions: Total Laparoscopic Hysterectomy; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer, Bladder Cancer
Interventions: PET/MRI; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Adnexal Mass, Ovarian Cancer
Interventions: Not listed
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: San Diego, California • Fort Collins, Colorado • Jupiter, Florida + 10 more

Search by objective public record fields.

Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery

Evaluating Tolerability of ePUHRT With Brachytherapy Boost

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Grid Therapy for Tumors of the Head, Neck, Thorax, Abdomen, Pelvis and Extremities.

An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer

Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Undergoing Prostatectomy

Prevention of Lymphoceles After Robotic PLND

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Quality of Life and Function of Patients With Pelvic Tumors After Undergoing Hemipelvectomy

Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy

Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development

Ovarian Cancer Risk Estimation in Patients With Pelvic Mass